
Bernardo Carpiniello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4974241/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. JAMA Psychiatry, 2018, 75, 396.	6.0	214
2	The Reciprocal Relationship between Suicidality and Stigma. Frontiers in Psychiatry, 2017, 8, 35.	1.3	121
3	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91.	4.8	96
4	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry, 2021, 78, 550.	6.0	89
5	Duration of untreated illness as a key to early intervention in schizophrenia: A review. Neuroscience Letters, 2018, 669, 59-67.	1.0	87
6	Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different "psychosocial―treatment approaches. Supportive Care in Cancer, 1996, 4, 129-140.	1.0	61
7	Serotonin Dysfunction, Aggressive Behavior, and Mental Illness: Exploring the Link Using a Dimensional Approach. ACS Chemical Neuroscience, 2017, 8, 961-972.	1.7	59
8	The asthma-anxiety connection. Respiratory Medicine, 2016, 120, 44-53.	1.3	56
9	The impact of COVID-19 lockdown and of the following "re-opening―period on specific and general psychopathology in people with Eating Disorders: the emergent role of internalizing symptoms. Journal of Affective Disorders, 2021, 285, 77-83.	2.0	54
10	Psychiatry during the Covid-19 pandemic: a survey on mental health departments in Italy. BMC Psychiatry, 2020, 20, 593.	1.1	53
11	Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 58, 1-7.	2.5	52
12	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. Psychiatry Research, 2017, 256, 359-364.	1.7	49
13	Risk and resilience factors for specific and general psychopathology worsening in people with Eating Disorders during COVID-19 pandemic: a retrospective Italian multicentre study. Eating and Weight Disorders, 2021, 26, 2443-2452.	1.2	47
14	Gender Differences in Remission and Recovery of Schizophrenic and Schizoaffective Patients: Preliminary Results of a Prospective Cohort Study. Schizophrenia Research and Treatment, 2012, 2012, 1-8.	0.7	45
15	The complex relationship between self-reported â€~personal recovery' and clinical recovery in schizophrenia. Schizophrenia Research, 2018, 192, 108-112.	1.1	45
16	Clinical and psychosocial outcome of patients affected by panic disorder with or without agoraphobia: results from a naturalistic follow-up study. European Psychiatry, 2002, 17, 394-398.	0.1	43
17	Assessment of eating disorders with the diabetes eating problems survey – revised (DEPS-R) in a representative sample of insulin-treated diabetic patients: a validation study in Italy. BMC Psychiatry, 2017, 17, 262.	1.1	43
18	<p>Challenges and Future Prospects of Precision Medicine in Psychiatry</p> . Pharmacogenomics and Personalized Medicine, 2020. Volume 13, 127-140.	0.4	42

BERNARDO CARPINIELLO

#	Article	IF	CITATIONS
19	Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? results of a retrospective study. Annals of General Psychiatry, 2012, 11, 21.	1.2	38
20	Mania Induced by Withdrawal of Treatment With Interferon Alfa. Archives of General Psychiatry, 1998, 55, 88.	13.8	37
21	Impulsivity and aggressiveness in bipolar disorder with co-morbid borderline personality disorder. Psychiatry Research, 2011, 188, 40-44.	1.7	37
22	Physical activity and mental disorders: A case–control study on attitudes, preferences and perceived barriers in Italy. Journal of Mental Health, 2013, 22, 492-500.	1.0	36
23	A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents. Clinical Therapeutics, 2014, 36, 1372-1388.e1.	1.1	35
24	Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders. Annals of General Psychiatry, 2015, 14, 6.	1.2	34
25	Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants. Biomedicines, 2020, 8, 311.	1.4	34
26	<p>The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1045-1060.	1.0	33
27	The Impact of Alexithymia on Treatment Response in Psychiatric Disorders: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 311.	1.3	31
28	Alexithymia in eating disorders: therapeutic implications. Psychology Research and Behavior Management, 2015, 8, 1.	1.3	30
29	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. European Psychiatry, 2020, 63, 1-21.	0.1	30
30	Pattern of gene expression in different stages of schizophrenia: Down-regulation of NPTX2 gene revealed by a meta-analysis of microarray datasets. European Neuropsychopharmacology, 2017, 27, 1054-1063.	0.3	28
31	Mass-media, violence and mental illness. Evidence from some Italian newspapers. Epidemiologia E Psichiatria Sociale, 2007, 16, 251-255.	1.0	27
32	Psychiatric Comorbidity and Quality of Life in Obese Patients. Results from a Case-Control Study. International Journal of Psychiatry in Medicine, 2009, 39, 63-78.	0.8	27
33	Obesity and psychopathology. A study of psychiatric comorbidity among patients attending a specialist obesity unit. Epidemiologia E Psichiatria Sociale, 2009, 18, 119-127.	1.0	26
34	Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics, 2020, 21, 533-540.	0.6	26
35	Violence and mental disorders. A retrospective study of people in charge of a community mental health center. International Journal of Law and Psychiatry, 2016, 47, 122-128.	0.5	24
36	Admixture analysis of age at symptom onset and age at disorder onset in a large sample of patients with obsessive–compulsive disorder. Journal of Affective Disorders, 2015, 187, 188-196.	2.0	23

BERNARDO CARPINIELLO

#	Article	IF	CITATIONS
37	Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. European Psychiatry, 2020, 63, e82.	0.1	23
38	Role of palmitoylethanolamide (PEA) in depression: Translational evidence. Journal of Affective Disorders, 2019, 255, 195-200.	2.0	22
39	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology, 2020, 45, 2229-2238.	2.8	21
40	Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. Biomedicines, 2021, 9, 875.	1.4	21
41	Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry, 2013, 13, 235.	1.1	20
42	Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Frontiers in Psychiatry, 2018, 9, 493.	1.3	20
43	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. European Psychiatry, 2020, 63, e98.	0.1	20
44	Mental health services in <scp>Italy</scp> during the <scp>COVID</scp> â€19 pandemic. Psychiatry and Clinical Neurosciences, 2020, 74, 442-443.	1.0	20
45	Association between psychiatric disorders and marfan's syndrome in a large sardinian family with a high prevalence of cardiac abnormalities. Clinical Cardiology, 1997, 20, 243-245.	0.7	19
46	Validation of the Italian version of the Compensatory Eating and Behaviors in Response to Alcohol Consumption Scale (CEBRACS). Eating Behaviors, 2015, 19, 120-126.	1.1	19
47	Unblending Borderline Personality and Bipolar Disorders. Journal of Psychiatric Research, 2017, 91, 90-97.	1.5	19
48	Peripheral Biomarkers in Schizophrenia: A Meta-Analysis of Microarray Gene Expression Datasets. International Journal of Neuropsychopharmacology, 2019, 22, 186-193.	1.0	19
49	Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders. Psychiatry Research, 2013, 210, 739-744.	1.7	18
50	Accuracy of self-assessment of real-life functioning in schizophrenia. NPJ Schizophrenia, 2021, 7, 11.	2.0	18
51	Biomarkers in aggression. Advances in Clinical Chemistry, 2019, 93, 169-237.	1.8	17
52	Depression and social change. From transcultural psychiatry to a constructivist model. Epidemiologia E Psichiatria Sociale, 2001, 10, 46-58.	1.0	16
53	Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy. International Journal of Mental Health Systems, 2015, 9, 37.	1.1	14
54	Clinical correlates of age at onset distribution in bipolar disorder: a comparison between diagnostic subgroups. International Journal of Bipolar Disorders, 2017, 5, 28.	0.8	14

#	Article	IF	CITATIONS
55	Renaming schizophrenia? A survey among psychiatrists, mental health service users and family members in Italy. Schizophrenia Research, 2021, 228, 502-509.	1.1	13
56	The Role of Gut Microbiota in the High-Risk Construct of Severe Mental Disorders: A Mini Review. Frontiers in Psychiatry, 2020, 11, 585769.	1.3	13
57	Diagnostic reliability in schizoaffective disorder. Bipolar Disorders, 2016, 18, 78-80.	1.1	12
58	A review and meta-analysis of gene expression profiles in suicide. European Neuropsychopharmacology, 2022, 56, 39-49.	0.3	12
59	Reliability, validity and acceptability of the WHOQOL-Bref in a sample of Italian psychiatric outpatients. Epidemiologia E Psichiatria Sociale, 2006, 15, 228-232.	1.0	11
60	Anatomical distribution and expression of <scp>CYP</scp> in humans: Neuropharmacological implications. Drug Development Research, 2021, 82, 628-667.	1.4	11
61	Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. International Journal of Bipolar Disorders, 2019, 7, 27.	0.8	11
62	Obesity and psychopathology. A study of psychiatric comorbidity among patients attending a specialist obesity unit. Epidemiologia E Psichiatria Sociale, 2009, 18, 119-27.	1.0	11
63	A multidisciplinary approach to mental illness: do inflammation, telomere length and microbiota form a loop? A protocol for a cross-sectional study on the complex relationship between inflammation, telomere length, gut microbiota and psychiatric disorders. BMJ Open, 2020, 10, e032513.	0.8	10
64	Autism spectrum in patients with schizophrenia: correlations with real-life functioning, resilience, and coping styles. CNS Spectrums, 2021, , 1-11.	0.7	10
65	Psychopathology, psychosocial factors and obesity. Rivista Di Psichiatria, 2016, 51, 30-6.	0.6	10
66	Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. Schizophrenia Research: Cognition, 2014, 1, 187-192.	0.7	9
67	Treating Depression: What Patients Want; Findings From a Randomized Controlled Trial in Primary Care. Psychosomatics, 2016, 57, 616-623.	2.5	9
68	Schizophrenia and "unmet needs― From diagnosis to care in Italy. European Psychiatry, 2020, 63, e26.	0.1	9
69	Leukocytosis Associated with Clozapine Treatment: A Case Series and Systematic Review of the Literature. Medicina (Lithuania), 2021, 57, 816.	0.8	9
70	Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia. Drug Design, Development and Therapy, 2016, 10, 1731.	2.0	8
71	Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals. Expert Review of Molecular Diagnostics, 2020, 20, 327-333.	1.5	7
72	Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia. International Journal of Methods in Psychiatric Research, 2021, 30, e1855.	1.1	7

#	Article	IF	CITATIONS
73	Melatonin and aggressive behavior: A systematic review of the literature on preclinical and clinical evidence. Journal of Pineal Research, 2022, 72, .	3.4	7
74	Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness. BMC Psychiatry, 2017, 17, 121.	1.1	6
75	Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study. Journal of Clinical Medicine, 2022, 11, 2517.	1.0	6
76	Depression in Diabetic Patients: What Is the Link With Eating Disorders? Results of a Study in a Representative Sample of Patients With Type 1 Diabetes. Frontiers in Psychiatry, 0, 13, .	1.3	6
77	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. BMJ Open, 2017, 7, e014938.	0.8	5
78	Personalized psychiatry: Promises and pitfalls. Neuroscience Letters, 2018, 669, 1-2.	1.0	5
79	The Italian Version of the Borderline Personality Disorder Severity Index IV: Psychometric Properties, Clinical Usefulness, and Possible Diagnostic Implications. Journal of Personality Disorders, 2018, 32, 207-219.	0.8	5
80	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54.	1.3	4
81	European Psychiatric Association policy paper on ethical aspects in communication with patients and their families. European Psychiatry, 2020, 63, e36.	0.1	4
82	How Is the History of Early Traumatic Exposure Associated With the Psychopathological Outcomes of COVID-19 Related Lockdown and Subsequent Re-opening in People With Eating Disorders?. Frontiers in Psychiatry, 2021, 12, 789344.	1.3	4
83	Delusional Infestation in a Patient with Renal Failure, Metabolic Syndrome, and Chronic Cerebrovascular Disease Treated with Aripiprazole: A Case Report. Case Reports in Medicine, 2011, 2011, 1-3.	0.3	3
84	First-episode Psychosis and Migration in Italy: Results from a Study in the Italian Mental Health Services (Pep-Ita Study). Journal of Immigrant and Minority Health, 2021, 23, 519-527.	0.8	3
85	Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia Research, 2022, 239, 34-41.	1.1	3
86	Anxious symptoms influence delayed-type hypersensitivity skin test in subjects devoid of any psychiatric morbidity. International Journal of Neuroscience, 1994, 79, 275-283.	0.8	2
87	Big data in severe mental illness: the role of electronic monitoring tools and metabolomics. Personalized Medicine, 2021, 18, 75-90.	0.8	2
88	Predominant Polarity and Polarity Index of Maintenance Treatments for Bipolar Disorder: A Validation Study in a Large Naturalistic Sample in Italy. Medicina (Lithuania), 2021, 57, 598.	0.8	2
89	Protocol for a pharmacogenetic study of antidepressants. Psychiatric Genetics, 2021, Publish Ahead of Print, 186-193.	0.6	1
90	Violence as aÂSocial, Clinical, and Forensic Problem. Comprehensive Approach To Psychiatry, 2020, , 3-24.	0.7	1

#	Article	IF	CITATIONS
91	Gut Microbiota Research in Bipolar Disorder and Possible Implications for Precision Psychiatry: A Systematic Review. Psychiatry International, 2022, 3, 114-121.	0.5	1
92	Gut microbiota and treatment-resistant schizophrenia: many questions, fewer answers. Pharmacogenomics, 2022, 23, 277-280.	0.6	1
93	Haloperidol and loss of gray matter in schizophrenia: Reconciling meta-analytical results with molecular pharmacology. Psychiatry Research, 2016, 235, 209-210.	1.7	Ο
94	Editorial: Decreasing the Impact of Treatment Resistance in Schizophrenia: Identifying Novel Molecular Targets/Pathways to Increase Treatment Efficacy. Frontiers in Pharmacology, 2020, 11, 1001.	1.6	0
95	Evolución clÃnica y psicosocial de los pacientes afectados por trastorno de angustia con o sin agorafobia: resultados de un estudio de seguimiento naturalista. European Psychiatry (Ed Española), 2003, 10, 228-233.	0.0	0